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ABSTRACT 
 
Evaluation of Serum Markers for Hyponatremia in Patients 
undergoing Neurosurgery 
  
 
Objective: 
 We conducted a prospective study to determine the usefulness of serum markers like NT 
proBNP, Aldosterone, Uric Acid and Antidiuretic hormone (ADH) in differentiating Syndrome 
of Inappropriate Anti-Diuretic Hormone (SIADH) and Cerebral Salt Wasting (CSW) in 
neurosurgical patients with postoperative hyponatremia with natriuresis (HWN).   
 
Methods: 
 Hyponatremia was defined as serum Na+ <130 mEq/l and natriuresis when urine spot 
sodium was >25mEq/l.  31 non trauma postoperative patients with HWN who met the inclusion 
criteria were included in our study. In Phase-1, central venous pressure (CVP) greater or less 
than 5 cm of water was used to differentiate SIADH from CSW in 10 patients with HWN. Based 
on the values of the serum markers we obtained a “cut-off” value of NT proBNP to distinguish 
SIADH and CSW.  In Phase-2 we used this cut-off value of NT proBNP to treat patients as 
SIADH or CSW until the serum Na+ normalized.  SIADH was managed with fluid restriction and 
oral salt.  Fluid replacement and oral salt was used for CSW.   
 
 
Results: 
  In Phase-1, of 6 patients treated as CSW, 5 patients had an NT proBNP level >125 
pg/ml, while of the 4 treated as SIADH, 3 had NT proBNP levels <125 pg/ml.  The sensitivity, 
specificity, positive predictive value and negative predictive value of the NT proBNP assay in 
this Phase were 83.3%, 75%, 83.3% and 75% respectively.   In Phase-2 (21 patients), an NT 
proBNP cut-off of 125pg/ml accurately diagnosed all 11 patients with SIADH and 9 of 10 
patients with CSW, all of whom responded to appropriate therapy. The mean time duration to 
correct hyponatremia in this Phase was 2.8 ± 1.63 days with a range of 1-8 days. The sensitivity, 
specificity, positive predictive value and negative predictive value of the NT proBNP assay were 
90%, 100%, 100% and 91.67% respectively. Overall the  sensitivity, specificity, positive 
predictive value and negative predictive value of the NT proBNP assay were 87.50%, 93.33%, 
93.33% and 87.50% respectively to distinguish SIADH from CSW (p value < 0.001). 
Aldosterone values were generally low in HWN. 
 
Conclusion: 
 NT proBNP is a useful serum marker to differentiate SIADH and CSW. Fludrocortisone 
would be beneficial in both SIADH and CSW. Serum Uric acid levels do not help differentiating 
SIADH from CSW. 
 
Keywords: 
 Aldosterone, Antidiuretic hormone, Cerebral Salt Wasting, Hyponatremia, NT proBNP, 
Syndrome of Inappropriate Antidiuretic hormone secretion, Uric Acid.  
 
 AIMS AND OBJECTIVES 
 
             To differentiate between the syndrome of inappropriate anti diuretic hormone(SIADH) secretion 
and cerebral salt wasting(CSW) using serum markers in non traumatic post-operative neurosurgical 
patients who develop hyponatremia and natriuresis. 
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INTRODUCTION 
 
Hyponatremia with natriuresis is a notorious entity in postoperative neurosurgical patients which can 
cause worsening of a patient's neurological status. However hyponatremia has also been detected in 
asymptomatic patients on routine laboratory testing.1 The main causes of hyponatremia with natriuresis 
have been attributed to syndrome of inappropriate anti diuretic hormone (SIADH) or cerebral salt 
wasting (CSW). While SIADH is associated with hypervolemic, CSW is associated with hypovolemic 
status. Hence patients with SIADH are treated with fluid restriction while those with CSW are treated 
with hydration. Studies have attempted to identify the volume status of patients using various clinical, 
laboratory and invasive (CVP) methods. However none of these methods are foolproof and hence a clear 
distinction between SIADH and CSW remains elusive. 
 
In our study we chose to look at some serum markers which we hoped would be a less invasive and a 
more reliable method to distinguish these two entities. 
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 REVIEW OF LITERATURE 
 
Hyponatremia is the most frequent electrolyte imbalance medical practitioners have to deal with.2 30% 
of patients admitted in hospitals have hyponatremia. It is linked with significantly higher death rates over 
a broad range of primary disorders. The prevalence of hyponatremia in Neurosurgical patients has been 
reported as high as 50%. 2 The incidence of postoperative hyponatremia in general has been reported to 
be between 1% to 5%.3 In a study by Chung et al4 over 1088 patients undergoing surgery, 4.4% 
developed hyponatremia inside 7 days. In their study hyponatremia was more common following organ 
transplantation, cardio - vascular, gastrointestinal surgery and accident surgery. In neurosurgical patients 
the incidence is higher in patients with subarachnoid hemorrhage, traumatic brain injury, brain tumors, 
and after pituitary surgery as compared with those with spinal lesions. Waikar et al5 in a prospective 
study on 98,411 patients have shown that patients with hyponatremia had elevated mortality rates in 
hospital at 1 and 5 years. This was even seen in those with mild hyponatremia (130-134 mEq/L).5 
Hyponatremia causes cerebral complications like brain edema, altered sensorium, seizures, vasospasm 
and death. 
 
The etiology of hyponatremia with natriuresis in patients undergoing neurosurgery is primarily due to 
either SIADH or CSW.2 
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Table 1: Cause of hyponatremia (serum sodium < 130 mmol/l) in 187 cases recorded in the 
neurosurgical unit of Beaumont Hospital between January 2002 and September 2003. 6 
 
 
Pathophysiology 
 
No. of patients 
(total = 187) 
 
% 
SIADH 116/187 62 
Hypovolemia 50/187 26.7 
Inappropriate iv fluids 7/187 3.7 
CSWS 9/187 4.8 
SIADH/CSWS 5/187 2.7 
 
Mild hyponatremia is defined as a serum sodium of 125 - 129 mEq/L. Moderate hyponatremia is defined 
as a serum sodium ranging from 120 - 124 mEq/L. Severe hyponatremia is defined as a serum sodium ≤ 
119 mEq/L.1 
 
Clinical Features 
The clinical symptomatology is due to brain edema, raised intracranial pressure and cerebral hypoxia.7 
Once the extracellular sodium levels fall following hyponatremia, water from the extracellular 
compartment flows into the intracellular compartment causing brain edema. The brain responds to this 
by expelling solutes from both compartments with accompanying water loss which in turn reduces 
intracerebral edema. 8  
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Early symptoms of hyponatremia include apathy, weakness, muscular cramps, nausea, vomiting, and 
headache. Later these patients develop impaired response to verbal and painful stimuli, hallucinations, 
urinary incontinence, and pulmonary edema. When the edema progresses, they develop varying degrees 
of raised intracranial tension and causing the brain to herniate. These may present with decorticate 
posturing, hypothermia and hyperthermia, central diabetes insipidus and mellitus, seizures, respiratory 
arrest, coma, permanent brain damage, and death. In a study of 740 patients by Ayus and Arieff 3, the 
frequency of hyponatremic encephalopathy was 8% with a morbidity rate of 52%. Increased intracranial 
tension and brain surgery tend to exacerbate the symptoms of hyponatremia. Many patients in 
Neurosurgical ICU's also have acidosis, hypoxia, or hypercapnia. 9 
 
  Acute hyponatremia 
Acute hyponatremia which develops in less than 48 hours causes grave symptoms. This is due to the 
limited time available for the brain to reduce the edema setting in before the brain herniates due to the 
volume constraints imposed by a rigid cranium. This could result in Cheyne-Stokes respiration, seizures, 
coma and herniation of the brainstem.8 
 
Chronic hyponatremia 
Here hyponatremia takes more than 48 hours to develop giving the brain sufficient time to set in adaptive 
mechanism to reduce cerebral edema. These patients therefore present with milder symptoms in the form 
of gait instability, falls, attention deficits and increased risk of fracture.8 
Based on the time gap between the neurological injury and the onset of hyponatremia Vingerhoets and 
de Tribolet10 classified hyponatremia into an acute syndrome (< 3 days) and the delayed syndrome (> 1 
week). Antidiuretic hormone levels were found to be raised in the first 3 days and thereafter the levels 
normalized or were depressed. They felt that the initial surge in the levels of ADH were appropriate 
rather than inappropriate and the hyponatremia resulting from this should be managed by fluid restriction 
while that of the chronic syndrome should be managed with salt and fluid supplementation as these were 
likely to be caused by CSW. 
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 Management of Water Equilibrium 
In normal individuals water intake depends on the serum osmolality which in turn is linked to the 
connection between antidiuretic hormone and thirst sensation. Dedicated neurons situated in the 
circumventricular organs of the hypothalamus are stimulated by elevations of plasma osmolality. This in 
turn stimulates production of ADH from the paraventricular and supraoptic nuclei. Neurosecretory 
granules located in the hypothalamus transport ADH for storage in the posterior pituitary where it will be 
released into the bloodstream on depolarization of osmoreceptors. ADH thus released in the bloodstream 
binds to V2 receptors in the collecting duct resulting in reabsorption of water from the urine via a 
mechanism involving aquaporin 2 terminals located on the luminal surface of the collecting duct.11 At 
the same time, a stimulus from the thirst centre of the brain encourages the individual to consume more 
water. Plasma osmolality and water intake are thus regulated by a combination of restricted water output 
mediated by ADH and increased water intake mediated by thirst. 9  
 
Role of intravenous fluids in the pathogenesis of postoperative hyponatremia 
In postsurgical patients, arginine vasopressin (AVP) levels are universally increased when compared 
with preoperative values. Despite abnormalities in AVP metabolism or renal function, hyponatremia 
does not develop unless excess free water is administered. Approximately 1% of patients develop 
hyponatremia postoperatively, and symptomatic hyponatremia occurs in approximately 20% of these 
patients. Following surgery some patients lose the ability to maintain their water equilibrium. In these 
patients even a relatively small quantity of 3 to 4 liters of intravenous hypotonic fluid  over 2 days can 
alter the plasma osmolality and serum sodium levels resulting in fatal hyponatremic encephalopathy  
postoperatively.3  Choice of fluids thus is of paramount importance in postoperative patients.3 
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TYPES OF HYPONATREMIA 
Plasma osmolality is normally sustained between 280 and 295 mOsm/kg by ADH. “Effective” solutes 
are those which are impervious to the cell membrane and remain with the extracellular fluid. Their 
concentrations are used to determine hypo-osmolality. Sodium and its allied anions are the major 
effective plasma solutes and therefore hyponatremia and hypo-osmolality are usually identical. There are 
however 2 situations where hyponatremia and hypo-osmolality do not coexist. 
 
Pseudo hyponatremia.  
Lipids and proteins inhabit a larger plasma volume that a molecule of water. Hence higher quantities of 
these molecules increases plasma volume and gives a false reading of low serum sodium. However, as 
the total number of particles in solute remains constant, plasma osmolality remains normal in these 
cases. 
 
Isotonic or hypertonic hyponatremia.  
Serum osmolality is a measure of the total number of effective solutes within a given volume of liquid. 
Effective solutes apart from sodium when present in higher quantities can increase osmolality of the ECF 
causing a transfer of water from the ICF to ECF. This in turn causes a dilutional hyponatremia. Glucose 
is an effective solute and hence hyperglycemia is a known cause of hyponatremia. Prolonged 
hyperglycemia can cause a glucose induced diuresis leading to hypertonic hyponatremia. In these 
patients it is better to assess osmolality by directly measuring serum osmolality or by correcting the 
measured serum sodium for the rise in glucose. Direct measurement of serum osmolality is also used in 
patients on mannitol or having received radiographic contrast as these constitute effective solutes.12 
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Pathogenesis of Hypotonic Hyponatremia 
Plasma osmolality is equal in both ICF and ECF as due to the fact that water can move unhindered 
across both these compartments. Na+ within the ECF and K+ within the ICF are the major determinants of 
plasma osmolality which is calculated by using the formula given below: 
OSMECF=OSMICF= (ECF solute+ICF solute)  = (2xNaE+2xKE+nonelectrolyte solute) 
                                            body water                                       body water 
OSMECF= osmolality of extracellular fluid 
OSMICF= osmolality of intracellular fluid 
 
The above formula shows us that hypotonic hyponatremia is caused by surplus water in the ECF due to 
either excess body water or by depletion of either Na or K or both. 12 
 
TYPES OF HYPOTONIC HYPONATREMIA 
Based on a patient's ECF volume status, hyponatremia is classified into hypovolemic, euvolemic, and 
hypervolemic hyponatremia. An exact measurement of the volume status of an individual is essential for 
this classification. 
 
Hypovolemic hyponatremia.  
In hypovolemic hyponatremia both total body water and total body sodium are decreased and greater 
decrease in total body sodium leads to hyponatremia. There is loss of sodium from either the kidney or 
elsewhere. Clinical signs of volume depletion include postural hypotension, increase in heart rate, drying 
of mucus membranes, reduced skin turgor. These clinical signs are neither sensitive nor specific. Urine 
spot sodium should be <25 mmol/L in these patients unless the kidney is the site of sodium loss. 12 
Causes of extra renal loss of sodium which occurs in these patients include vomiting, diarrhea, 
pancreatitis, burns, and sweating. 
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Euvolemic hyponatremia. 
In euvolemic hyponatremia total body sodium remains slightly low normal while total body water is 
increased, leading to hyponatremia. Many different hypo-osmolar disorders can present with SIADH 
which causes this form of hyponatremia. Patients without clinical signs of volume depletion or volume 
expansion (subcutaneous edema, ascites) are considered to be euvolemic unless evidence points to an 
abnormal ECF volume. Urine spot sodium should be ≥25 mmol/L in these patients. 12 
 
Hypervolemic hyponatremia.  
In hypervolemic hyponatremia there is an increase in both total body water and total body sodium. In 
these patients excretion of body water is decreased causing a dilutional effect on the available serum 
sodium.  Hyponatremia with volume excess in the extracellular space can arise with many diseases. 
Clinical signs of volume excess include subcutaneous edema, ascites and pulmonary edema. In these 
patients the urine sodium is usually <25 mmol/L due to activation of the renin-angiotensin-aldosterone 
system (RAAS) with secondary renal sodium conservation despite the whole-body volume overload. 12 
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 Table 2: Differential diagnosis of hyponatremia based on urinary spot [Na+]13.  
 
 Urine [Na+] <20 mmol/L Urine [Na+] >40 mmol/L 
Hypovolemia 
(dry tongue, decreased CVP, 
increased urea,increased pulse, 
decreased BP) 
Vomiting, diarrhea, 
skin losses, burns 
Diuretics, Addison’s, 
cerebral salt-wasting syndrome,
salt-losing nephropathy 
Euvolemia Hypothyroidism 
Any cause + hypotonic fluids 
SIADH 
Glucocorticoid deficiency 
Drugs 
Hypervolemic 
(edema, ascites, LVF, increased JVP,
increased CVP) 
CCF, cirrhosis 
Nephrotic syndrome 
Renal failure,  
any cause + diuretics 
BP = blood pressure; CCF = congestive cardiac failure; CVP = central venous pressure; LVF = left 
ventricular failure; JVP = jugular venous pressure; SIADH = syndrome of inappropriate secretion of 
antidiuretic hormone. 
 
PATHOPHYSIOLOGY OF HYPOTONIC HYPONATREMIA 
Hypovolemic Hyponatremia 
Gastrointestinal disease 
 Prolonged vomiting and diarrhea leads to loss of gastric contents and stool (which are hypotonic) 
ultimately leading to volume depletion and hypernatremia. This stimulates ADH secretion. When 
patients take in a lot of fluids and food low in sodium in this setting, they develop hyponatremia. Urine 
spot sodium will be low if the patient has diarrhea or high if the patient has persistent vomiting. 12 
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 Diuretic therapy  
Diuretics cause loss of sodium from the kidneys and adversely affect the ability of distal tubules to dilute 
urine. Renal excretion of sodium results in a high urine [Na+] level. Thiazide drugs and furosemide are 
the most common cause of diuretic induced hyponatremia. 12 
Mineralocorticoid deficiency  
Occurs in primary adrenal insufficiency where sodium is lost through the kidneys leading to 
hypovolemia which then secondarily stimulates AVP release. Volume loss with high urine spot sodium 
and associated hyperkalemia is indicative of this condition. A low urinary potassium verifies the 
diagnosis. In these patients corticosteroids must be given immediately even as blood tests to measure 
cortisol, aldosterone, and ACTH levels are being done. 12 
 
Euvolemic Hyponatremia 
Glucocorticoid deficiency 
Low levels of ACTH caused by pituitary dysfunction leads to deficient hormone secretion by the 
adrenals resulting in this condition. Glucocorticoid deficiency diminishes water excretion due to non-
osmotic AVP secretion. Maintenance of adequate aldosterone levels prevents renal sodium loss acting 
synergistically to prevent decrease in ECF levels. 12  
Hypothyroidism 
Hypothyroidism causes changes in renal perfusion and glomerular filtration rate (GFR) secondary to 
systemic effects of thyroid hormone deficiency on cardiac output and peripheral vascular resistance. 
Plasma AVP levels become elevated when the hypothyroidism becomes severe and the effective arterial 
blood volume reduces enough to stimulate AVP secretion. Serum ADH levels are elevated in patients 
with cardiac dysfunction due to severe myxedema. 12 
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Decreased solute consumption 
Patients consuming large quantities of beer with minimal food intake, and those on very low protein diet 
tend to develop euvolemic hyponatremia. The hyponatremia in these patients is neither dilutional nor 
depletional. 12 
 
Primary polydypsia 
Many patients with acute psychosis secondary to schizophrenia, sarcoidosis or brain tumours tend to 
have impaired excretion of solute free water. Excess intake of water by these patients tends to produce 
hyponatremia.12 
 
Figure 1: An algorithm for the differential diagnosis of hyponatremia based on assessment of volume 
status and measurement of urine spot sodium has been shown below13 
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Syndrome of Inappropriate Anti Diuretic Hormone secretion(SIADH) 
This condition is an electrolyte imbalance in which low levels of serum sodium is caused by impaired 
urinary dilution due to an inappropriately elevated level of ADH. These patients are characterized by the 
absence of any osmotic imbalance or renal dysfunction.14 
 
Table 3:  Causes of the Syndrome of Inappropriate Antidiuretic Hormone (SIADH)15  
Mechanism Etiology 
Increased secretion of ADH Central nervous system: stroke, hemorrhage, 
infection, trauma, psychosis 
Drugs (most common): cyclophosphamide, 
vincristine, vinblastine, amiodarone, 
ciprofloxacin, theophylline, antipsychotic 
drugs (haloperidol, thioridazine, thiothixene), 
TCAs, MAOIs, bromocriptine, 
carbamazepine, clofibrate 
Pulmonary conditions: pneumonia, tuberculosis,
acute respiratory failure, asthma, 
atelectasis 
Postoperative states: major abdominal or 
thoracic surgeries 
Ectopic secretion of ADH Lung cancers, tumors of duodenum and 
pancreas, olfactory neuroblastoma, 
malignant histiocytosis, mesothelioma, 
occult tumors 
Increased sensitivity to ADH NSAIDs, cyclophosphamide, tolbutamide, 
carbamazepine, mizoribine, chlorpropamide 
Miscellaneous Exogenous administration of vasopressin, 
desmopressin 
Cachexia, malnutrition, AIDS 
 
ADH = antidiuretic hormone; MAOIs = monoamine oxidase inhibitors; NSAIDs = nonsteroidal anti-
inflammatory drugs; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic antidepressants. 
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Diagnostic Criteria (European Hyponatremia Network)  13 
Essential diagnostic criteria for SIADH13 
• Decreased measured serum osmolality (<275 mOsm/kg H2O) 
• Urinary osmolality >100 mOsm/kg H2O during hypo-osmolality 
• Clinical Euvolemia 
  - No clinical signs of contraction of extracellular fluid (e.g., no orthostasis (a), tachycardia,     decreased 
skin turgor or dry mucous membranes) 
  - No clinical signs of expansion of extracellular fluid (e.g., no edema or ascites) 
• Urinary [Na+] >40 mmol/L with normal dietary sodium intake (b) 
• Normal thyroid and adrenal function determined by both clinical and laboratory assessment 
• No use of diuretic agents within the week prior to evaluation 
 
Supporting diagnostic criteria for SIADH13 
• Serum uric acid <4 mg/dL (<0.24 mmol/L) 
• Blood urea nitrogen <10 mg/dL (<3.57 mmol/L) 
• Fractional sodium excretion >1%; fractional urea excretion >55% (c) 
• Failure to improve or worsening of hyponatremia after 0.9% saline infusion 
• Improvement of hyponatremia with fluid restriction 
a) Orthostatic changes in blood pressure and pulse rate are defined as a ≥20mmHg decrease in systolic 
blood pressure and/or ≥20bpm increase in the pulse rate upon going from the supine to standing 
position.13 
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b) Although high urine sodium excretion generally occurs in patients with SIADH, its presence does not 
confirm the diagnosis, nor does its absence rule out the diagnosis; urine [Na+] can also be high in 
patients with Addison’s disease.13  
Conversely, some patients with SIADH can have low urinary [Na+] if they become hypovolemic or 
solute depleted, which are conditions sometimes produced by imposed sodium and water restriction.13 
c) Fractional sodium excretion = (urinary sodium excretion/serum sodium)/(urinary creatinine/serum 
creatinine)×100;13 
Fractional urea excretion = (urinary urea/serum urea)/(urinary creatinine/serum creatinine)×100.13  
Urine sodium excretion aids in distinguishing hypo-osmolality caused by a decreased effective arterial 
blood volume (in which case urine Na+ is low due to renal conservation of Na+ ) from dilutional 
disorders in which renal Na+ excretion is normal or increased owing to ECF volume expansion. 
However, urine [Na+] can also be high in renal causes of solute depletion such as diuretic use or 
Addison’s disease. On the other hand, patients with SIADH can have low urine [Na+] levels if they later 
develop hypovolemia or solute depletion. Therefore, although high urine [Na+] excretion generally 
occurs in patients with SIADH, its presence does not confirm this diagnosis, nor does its absence rule out 
the diagnosis. 12 
 
Pathophysiology 
Antidiuretic hormone (ADH) reduces the rate of urinary water loss. Therefore if a patient were to take 
surplus water, ADH would prevent excretion of the excess water. This would in turn increase the total 
body water further diluting the available sodium and causing hyponatremia. The amount of water 
required to do this would also depend of the quantity of free water excreted. In patients suffering from 
psychogenic polydypsia, a mild impairment of solute excretion would be enough to retain body water 
and dilute serum sodium. On the other hand, patients with high urinary concentration are constantly high 
require only a small amount of water intake to produce a similar imbalance.14  
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There are 2 mechanisms of by which an increase in body water such as that which occurs in SIADH 
causes hyponatremia. The first is by dilution where the serum sodium decreases in a manner 
proportionate to the elevation in total body water. The other mechanism is a net reduction in the sodium l 
available for exchange. Decrease in aldosterone secretion and elevated atrial natriuretic peptide levels 
cause natriuresis. In some patients vomiting induced by the hyponatremia itself tends to worsen the 
hyponatremia .14 
 
Types of defective Urinary Water Excretion 
Gary .L. Robertson14 identified 4 types of inappropriate urine excretion. In 3 of these types, the 
osmoregulation of plasma AVP is abnormal because neither the hormone nor the urine concentration is 
fully suppressed as they should be when plasma sodium falls below the normal range. 
 
 
Figure 2:  4 types of ADH secretion in patients with SIADH. 1 mEq/L = 1 mmol/L.14 
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 Type A: This pattern occurs in about 30% of SIADH and is characterized by an erratic, unregulated 
release of AVP in a level above that which produces maximum restriction of urination. Thus, changes in 
urinary concentration are minimal and the urine osmolarity remains fixed at the highest level (urine 
concentrating capacity is impaired in SIADH).14 
 
Type B: This pattern occurs in another 30% of SIADH. Here an insult to the posterior pituitary gland or 
damage to the factors inhibiting ADH secretion cause a small constant release of ADH which rises to 
appropriate levels once serum osmolality and serum sodium are within normal limits. Urinary 
concentration levels are fixed at a range below that in type A (Figure 2).14 
 
Type C: (Figure 2) This pattern also occurs in about 30% of SIADH. Here an insult to the peripheral 
mechanisms which control ADH secretion via baroreceptors causes a downward resetting of the entire 
osmoregulatory system. Patients with this disorder have low ADH levels when hyponatremic but 
inappropriately high levels when the plasma osmolarity and sodium levels start correcting and much 
before the hyponatremia is corrected.14 
 
Type D (Figure 2): There is no aberration in the regulation of ADH (Figure 1). The exact cause of this 
defect is unknown. Mechanisms postulated include activation of the V2 receptor of ADH by genetic 
mutation, existence of an antidiuretic factor other than ADH or aberrant transportation of aquaporin 2 
water channels mediating water reabsorption. These patients do not have any demonstrable ADH in 
serum under hyponatremic conditions and have normal cortisol levels. They fail to dilute their urine even 
when given an oral water load (Figure 2). 14  
 
There is no connection between the cause of SIADH and the type of osmoregulatory defect. 14 
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 Figure 3:  Effect of an oral water load on AVP, urine osmolarity (UOsm) (expressed as milliosmoles per 
liter), urine flow (urine volume [UVol] in milliliters per 30 minutes), and plasma (serum) sodium (PNa) 
in patients with osmoregulatory defect types A, B, C, and D. 1 mEq/L = 1 mmol/L 14. 
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Management of SIADH 12 
Patients with SIADH who present with acute symptomatic hyponatremia are best treated with hypertonic 
(3%) saline given as a continuous infusion as they may not respond adequately to isotonic saline. 
Volume overload can be treated with intravenous furosemide, especially in patients with known 
cardiovascular disease. Correction is stopped when either: (1) patient becomes asymptomatic; or (2) a 
total correction of 18 mmol/L is achieved. Serum sodium is verified at regular periods to ensure the rate 
of correction. Serum sodium need not be normalized immediately but rather brought to a level of safety. 
Some patients excrete water to spontaneously rectify their hyponatremia. 
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Measured correction of chronic hyponatremia to < 10 - 12 mmol/L in 24 hours and to < 18 mmol/L in 48 
hours ensures a slow reuptake of organic osmolytes by the brain. This helps in preventing osmotic 
demyelination syndrome. This syndrome is more common in the malnourished, alcoholics and those 
with severe liver disease. In high-risk patients, treatment should be aimed to stay beneath limits that have 
been laid out in patients without these risk factors. Severe demyelinating brain lesions rarely occur when 
the rate of correction > 25 mmol/L in 48 hours (based on patients with autopsy-proven myelinolysis). 
 
 In patients with acute hyponatremia such as those with water intoxication, the risk of developing 
osmotic demyelination with treatment is low. However, patients with chronic hyponatremia such as 
those with who have stopped treatment with desmopressin, those with cortisol deficiency, etc are at risk 
of developing this syndrome and hence their therapy should be controlled to limit the rate of correction 
of serum sodium using the end points mentioned above. 
 
 Patients with reset osmostat syndrome generally do not require treatment as the hyponatremia of such 
patients only varies around their reset level of serum sodium. Fluid restriction is the management of 
choice for SIADH. There should be no restriction of sodium in diet. Fluid restriction should include all 
kinds of fluids and requires to be continued for many days before correction of hyponatremia. The 
quantity of fluid restriction required depends on urine output plus insensible fluid loss (nonfood, fluids 
should be limited to 500 mL/day below the average daily urine volume);  
 
Patients with chronic SIADH due to continuous loss of sodium from the urine require a high salt intake 
unless otherwise contraindicated. Failure of significant fluid restriction after several days of confirmed 
negative fluid balance should raise the possibility of other causes, including solute depletion and 
clinically unapparent hypovolemia.  
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When fluid restriction is started, drugs known to cause SIADH should be stopped. Pharmacologic 
intervention is reserved for refractory cases.  
Demeclocycline is the agent of choice in SIADH. The drug causes a diuresis decreasing urine 
concentration even in the presence of high serum ADH levels. The dose of this drug ranges between 600 
to 1,200 mg/day in divided doses. The drug takes many days to achieve maximal diuretic effects. Side 
effects include reversible azotemia and renal toxicity. Renal function should be monitored regularly in 
patients treated with demeclocycline and the medication should be discontinued if increasing azotemia is 
noted.  
 
Other medicines described include lithium and urea which however have not found favor due to 
inconsistent results and significant side effects and toxicities.  
 
Other drugs that decrease AVP hyper secretion (e.g., diphenylhydantoin, opiates, ethanol),  are erratic 
and unpredictable. An exception is the ĸ-opioid receptors agonists, which are more specific for inhibition 
of AVP hyper secretion in animal studies and in clinical trials have successfully produced diuresis in 
patients with cirrhosis. 
 
Vasopressin Receptor Antagonists 16 
By binding to the V2 receptor of the principal cell of the collecting duct, VRAs inhibit the renal action of 
arginine vasopressin, thereby stimulating water excretion and increasing serum Na+. Drugs that block the 
action of AVP V2R selectively facilitate water excretion while sparing the solutes, and are therefore 
called aquaretic, as against diuretics which cause both water and solute excretion. 
 Conivaptan, a drug that blocks the mixed V1a/V2 receptor (V1a/V2RA), and tolvaptan, which 
selectively blocks the V2 receptor (V2RA), have recently been approved for treatment of hyponatremia 
with mild-to moderate symptomatology. Other V2RAs include satavaptan and lixivaptan.  
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Several randomized controlled trials have examined the efficacy and safety of VRAs in treating 
hyponatremia. VRAs are effective at raising serum Na+ and effective water clearance in hyponatremia 
during the first 5 days of study. Short-term efficacy was greater in Euvolemic hyponatremia and high-
dose VRAs. Meaningful increases in serum Na+ occur by day 1 of VRA administration, practically 
without fluid restriction. 
 
Cerebral Salt Wasting Syndrome 
Cerebral salt wasting was identified in the 1950s when studies described the presence of polyuria, 
elevated urinary sodium levels, and dehydration despite the presence of a low serum sodium 
concentration and adequate fluid intake.  
 
The exact frequency of CSW is not clear. This issue has been studied most rigorously in patients with 
aneurysmal SAH. In one study by Wijdicks EF et al 17 up to 67% (six of nine) of patients with 
hyponatremia after rupture of an intracranial aneurysm had CSW as the etiology of low sodium levels 
and 75% (six of eight) of SAH cases in another study by Nelson et al 18 also had CSW. A study by 
Sherlock et al 6 however, found that only 6.5% (4 of 62) of patients who presented with spontaneous 
SAH and subsequent hyponatremia had CSW as the cause of abnormally low sodium levels in their 
unselected cohort. The discrepancy between reported prevalence rates is a result of differences in study 
population size and with how CSW and volume depletion are defined 19. There is no universally 
accepted gold standard in defining extracellular volume status or the specific parameters that classify 
cerebral-induced salt wasting, leading to significant variability between studies in the definition of low 
intravascular volume. For example, some authors have measured central venous pressure (CVP), 
whereas others have used isotope-labeled albumin. This difference in method of volume assessment and 
inclusion criteria could result in varying frequencies of affected. An additional confounding variable 
underlying the variability of CSW frequency in the literature is the manner in which sodium depletion is 
defined. Single versus multiple day cumulative sodium balance measurements often yield significantly 
different results 19. 
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CSW has been associated with a host of other CNS diseases in addition to aneurysmal SAH. Vespa 
estimated that 5% to 10% of traumatic brain injury patients to have salt wasting 19. CSW is also seen in 
infectious meningitis, transsphenoidal pituitary surgery and cerebral malignancies, such as primitive 
neuro ectodermal tumors with intra ventricular dissemination, carcinomatous meningitis, glioma, and 
primary CNS lymphoma. 
 
Pathogenesis 
Despite the clear association between the presence of CSW and severe neurologic disease, the 
mechanism underlying this association has not been clearly identified. 
 
Renin-Angiotensin-Aldosterone System 
Renin is a circulating enzyme produced and stored within the kidney and released in response to low 
systemic and renal arterial perfusion. This hormone initiates a series of enzymatic steps involving the 
well known angiotensin-converting enzyme, resulting in the formation of angiotensin II (AT II). 
 
 Renin increases the sympathetic tone and stimulates the release of ADH. In the process it causes 
peripheral vasoconstriction and raises the blood pressure. The renal blood flow is thus increased and an 
appropriate rate of glomerular filtration and the percentage of sodium to be filtered are thus maintained. 
Aldosterone which is released in the process regulates extracellular fluid volume and serum potassium 
concentration thereby maintaining serum sodium homeostasis. RAAS activity is increased during periods 
of low circulating fluid volume and decreased when total circulating volume is sufficient or elevated. 
Neuronal synthesis of ATII takes place within the paraventricular nucleus and is released in the rostral 
ventrolateral medulla, a critical structure in the autonomic neural control of circulation. This implies a 
cerebrally mediated mechanism for influencing RAAS system exists. Tonic excitation of the rostral 
ventrolateral medulla influenced by endogenous AT II has been postulated to result in increased 
peripheral sympathetic tone. 19 
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Sympathetic Nervous System Hypothesis 
The autonomic nervous system increases the sympathetic tone during periods of intravascular depletion 
causing the secretion of renin from the kidneys. This stimulates the RAAS causing sodium and water 
retention. AT II by way of a positive feedback mechanism regulates the sympathetic nervous system 
activity by binding to specific receptors located within the subfornical organ (SFO) and area postrema. 
The SFO has direct projections to the paraventricular nucleus which are thought to control the activity of 
the rostral ventrolateral medulla causing an increase in the activity of the sympathetic nervous system by 
their projections to preganglionic sympathetic neurons within the intermediolateral cell column of the 
spinal cord. 19 
However, it has yet to be demonstrated that the changes in the interactions between the autonomic 
nervous system and the kidneys that are needed to produce a salt wasting state actually occur in the 
setting of acute cerebral injury. 19 
 
Natriuretic Peptide Theory 
In the 1980s after it was discovered that atrial myocardial extracts induced a potent natriuretic response 
when infused into rats. These were called Natriuretic peptides. Contemporary studies looking into the 
origin of sodium and extracellular volume dysfunction in patients with SAH led to the realization that a 
natriuretic factor may be involved. A number of natriuretic substances have been discovered. These 
molecules defend against periods of excess water and salt retention by inhibiting the RAAS system, 
stimulating vascular relaxation, stopping both the excess sympathetic outflow and the generation of 
vasoconstrictor peptides. Four main natriuretic peptides with supposed associations with CSW have been 
identified: (a) atrial natriuretic peptide (ANP); (b) brain-natriuretic peptide (BNP); (c) C-type natriuretic 
peptide (CNP) (d) dendroaspis natriuretic peptide (DNP). The first three of these peptides are present 
within the CNS and have a tissue-specific site of production: ANP and DNP originate from the 
myocardial atria; BNP from the ventricles of the heart and CNP from the telencephalon, hypothalamus, 
and endothelium. 19 
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The natriuretic peptides reduce the vascular sympathetic tone thereby dilating the smooth muscles of the 
the arteries and veins and leading to an increase in the glomerular filtration rate. These molecules also 
impair angiotensin mediated sodium reabsorption and resist the action of vasopressin at the collecting 
ducts. Natriuretic peptides produced locally within the adrenal medulla have inhibitory effects on 
mineralocorticoid synthesis causing low levels of aldosterone in the presence of hypovolemia.19  
 
Several studies have shown elevated serum BNP after subarachnoid hemorrhage.  McGirt et al 20 showed 
a time bound association between elevated BNP levels and hyponatremia in patients with SAH as well as 
presence of cerebral vasospasm. Besides BNP, other members within this peptide family, ANP in 
particular, have also been suspected to contribute to the development of CSW. Lately DNP, has also 
been implicated as a causative agent of hyponatremia in cases of aneurysmal SAH. More research would 
be required to work out more clearly the mechanism of action of each natriuretic peptide. 19 
 
Other theories 
Kojima et al suggested that a mechanism other than one involving ANP, BNP, or ADH may be 
responsible for CSW based on their experiments on rats where rats with CSW were found to have levels 
of ANP decreased, while the BNP and ADH concentrations were unchanged. They concluded that a new, 
undetermined mechanism or one that involves DNP, likely underlies the etiology of CSW. 19 
 
Adrenomedullin (AM) a recently discovered endogenous peptide has also been proposed as a mediator 
of CSW. AM is a potent vasodilator with natriuretic and diuretic properties and elevation of serum levels 
of this peptide occurs immediately after SAH. The release of this hormone in aneurysmal SAH might 
serve a protective role against the development or worsening of cerebral vasospasm through its 
vasoactive properties. The site of CNS production of AM within the hypothalamus extends neuronal 
projections to regions within the brainstem and spinal cord, which can decrease sympathetic tone.19  
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Although new molecules and mechanisms have been described, BNP and ANP continue to be implicated 
as the main offenders toward the development of CSW, of which the former continues to be of primary 
suspect. 
 
 
Figure 4: A proposed mechanism for the pathogenesis of cerebral salt wasting. IMCD, inner medullary 
collecting duct; EABV, effective arterial blood volume; AVP, arginine vasopressin; BNP, brain 
natriuretic peptide; ANP, atrial natriuretic peptide 21 
 
Management of Hypovolemic Hyponatremia12 
The first step in the management of hypovolemic hyponatremia is the establishment of hyponatremia. 
One need to only correct the volume deficit thereafter and the sodium would correct subsequently. In 
patients who are dehydrated and also hyponatremic, correction of volume deficit would often have been 
started even before the results of blood tests have been obtained. 
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Fluid resuscitation should be pursued until the blood pressure normalizes. A diagnostic cum therapeutic 
challenge with isotonic saline when the volume status and/or diagnosis are ambiguous. Hypovolemic 
hyponatremia most often, except in cerebral salt wasting and thiazide induced diuresis, is chronic. 
Treatment of such cases therefore does not include the use of hypertonic saline. If 3% saline is to be used 
care must be taken to start the diuretic only after the patient is euvolemic.   
 
Previous studies from our department had attempted to draw out a treatment strategy for hyponatremia 
with natriuresis based on blood volume status and hematocrit. Sivakumar et al22 studied 21 patients and 3 
control patients. Patients with hyponatremia were divided into 3 groups based on hematocrit, central 
venous pressure, and total blood volume. Group A which consisted of 16 patients who had hypovolemia 
and anemia. Group B patients included 5 patients with only hypovolemia. There were no patients in 
Group C which was for patients with hypervolemic. Patients in Groups A and B were treated with salt 
and isotonic fluid supplementation. An additional 500 ml of whole blood was given to patients in Group 
A. Hyponatremia was corrected in all the patients within 72 hours. The authors concluded that CSW was 
the most common cause of hyponatremia with natriuresis as most cases of hyponatremia are associated 
with hypovolemia. 
 
Thereafter Damaraju et al.1 tried to validate the protocol developed by Sivakumar et al22 using central 
venous pressure as the sole measure of volume status of patients with hyponatremia and natriuresis. 26 
cases were recruited into their study. Central venous pressure was used to classify patients as 
hypovolemic (<5 cm of water), normovolemic (6-10 cm of water), or hypervolemic (>11 cm of water). 
Hypovolemic patients were given fluids and salt. Euvolemic patients were given 12 g of salt per day in 
addition to normal fluids. Patients with anemia were transfused whole blood.  They concluded that 
hyponatremia with natriuresis could be managed with guidance of volume status as determined by the 
central venous pressure and that the syndrome of hyponatremia with natriuresis was most often caused 
by CSW. 
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Serum Anti Diuretic Hormone (ADH):  
ADH is a nanopeptide which is also referred to as Arginine Vasopressin (AVP). Neurons of the 
supraoptic and paraventricular nuclei produce ADH, transport them through the pituitary stalk and store 
them in the capillary plexus of the neurohypophysis. These plexuses drain into the systemic circulation 
through the cavernous sinus and the superior vena cava. 23 
 
The primary function of AVP is to decrease urine output. ADH binds to V2 receptors to increase the 
production of C-AMP which in turn increases the permeability of the luminal surface of the collecting 
duct through the expression of water channels called aquaporin 2. These water channels transport water 
back into the renal medulla increasing the urine concentration and reducing the urine output. 23 
 
Specialized osmoreceptors present near the supraoptic nucleus mediated the osmoregulation of ADH. 
They are sensitive to minute changes in plasma osmolality as small as 1%. When the serum osmolality 
reduces, ADH secretion is suppressed thereby permitting maximum water excretion through the urine. 
Even a minute increase in serum osmolality causes ADH levels to increase dramatically to maximally 
inhibit water excretion thereby keeping serum osmolality and sodium within the normal range 275 - 295 
mOsm/kg. The sensitivity of the ADH response to osmotic stimulation varies widely. 
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 Figure 5: The relationship of plasma ADH to plasma osmolality in healthy adults 23 
 
Reduction in blood volume or arterial pressure of more than 10% to 20% can cause release of ADH. 
Other stimuli for ADH include nausea and vasovagal reactions. Emotional stress per se does not cause 
ADH release unless it also induces a vasovagal reaction. 23 
 
Inappropriate secretion of ADH is the main pathophysiology in SIADH. The main stimulus for the 
release of ADH from the supraoptic and paraventricular hypothalamic nuclei is hypernatremia of the 
blood perfusing the anterior hypothalamus. It can also be released in response to hypovolemia or 
hypotension even if the plasma is hypotonic. However in SIADH the ADH secretion is not suppressed 
by either hypotonia or normotensive normovolemia 24,25. This ADH secretion causes water retention by 
the kidneys, increased the total body water and extracellular fluid volume, suppresses the renin- 
angiotensin-aldosterone mechanism and releases natriuretic substances.  
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Serum NT pro-BNP (N-terminal pro b-type natriuretic peptide): 
The natriuretic peptides are a family of molecules consisting of several structurally-related hormones. At 
present, the natriuretic peptide family includes atrial natriuretic peptide (ANP), B-type (or brain) 
natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and dendroaspis natriuretic peptide (DNP) 26 
 
B-type natriuretic peptides are produced initially as a 134 amino acid pre-pro-peptide and cleaved into 
proBNP108, a precursor molecule which is stored in the secretory granules in myocytes. Upon release, 
proBNP108 is cleaved by a protease known as furin into N-terminal (NT)-proBNP (a 76 amino acid 
biologically-inert portion), and BNP (which is biologically active). In humans, NT-proBNP and BNP are 
found in largest concentration in the left ventricular (LV) myocardium, but are also detectable in atrial 
tissue as well as in the myocardium of the right ventricle. 26 
 
Figure 6: Schematic drawing of proBNP showing enzymatic cleavage into biologically active BNP and 
NT-proBNP. Hall C Eur J Heart Fail 2004;6:257-260 27                                                                                            
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BNP is a cardiac hormone with natriuretic, vasorelaxant, aldosterone inhibitor and sympathetic outflow 
inhibiting properties.19,28 It has been implicated in the development of CSW by inhibiting angiotensin 
induced sodium reabsorption at the proximal convoluted tubule and opposing the action of vasopressin at 
the collecting ducts. It also inhibits the synthesis of mineralocorticoids. 19  In addition to being found in 
the atria of the heart and stored in the cardiac ventricles, it is also stored in the hypothalamus. 29 
 
Although BNP and NTproBNP are derivatives of the same basic compound, they have certain 
differences which are significant in the clinical setting. BNP is circulated in the bloodstream as a 
biologically active compound which means it also is actively cleared from the plasma by neutral 
endopeptidases and natriuretic peptide receptors. It has a short half life of less than 20 minutes. Also, 
BNP cannot be used as a reliable marker as its concentration drops invitro as time progresses. BNP 
activates the kallikrein system when collected in glass tubes and causes a drop in the serum value. 
NTproBNP on the other hand being a precursor is stable both in vivo and invitro. It has a long half life of 
up to 120 minutes and can be kept in glass tubes for more than 72 hours, thus posing a striking advantage 
as a serum marker for hyponatremia.26  The NT-proBNP assay is more sensitive than the BNP assay. 26 
 
Serum Aldosterone: 
Aldosterone is a mineralocorticoid that is produced in the adrenal gland and forms part of the renin 
angiotensin aldosterone system (RAAS) which plays a central role in maintaining whole body sodium 
and water homeostasis. Aldosterone and ATII work synchronously to effect reabsorption of sodium from 
the distal tubules. Aldosterone forms a complex with the mineralocorticoid receptor in the distal tubule 
which travels inward into the cell nucleus to induce gene transcription. This process produces certain 
proteins that facilitate sodium reabsorption by several mechanisms, which are listed below.  
 
1) Increasing sodium-potassium ATPase protein and activity at basolateral membranes of distal nephron 
segments. 
2) Increasing the activity of enzymes of the tricarboxylic acid cycle. 
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3) Increasing the production of ATP to be used as an energy source for the sodium-potassium ATPase 
pump. 
4) Increasing the expression and activation of epithelial sodium channels, which enhances sodium entry 
into the cell. 
5) Increasing the permeability of the apical membrane to potassium, which drives the ATPase pump. 
 
Taken together, the activation of multiple sodium transport mechanisms leads to augmented sodium and 
water reabsorption by the kidney. 30 Aldosterone is inhibited by natriuretic peptides and its serum levels 
are decreased in CSW and normal or high in SIADH. 28,29,31  The normal range of serum aldosterone 
varies between 40-310 pg/ml in the upright posture and between 10-160 pg/ml in the recumbent posture. 
 
Serum Uric acid: 
Uric acid (UA) is the final product of purine degradation with xanthine oxidase. Approximately 70% of 
the UA is excreted through the kidneys and 30% of the UA is excreted through the gastrointestinal tract. 
Beck 32 proposed that the coexistence of hyponatremia and hypouricemia (defined as serum urate less 
than or equal to 4 mg per 100 ml) differentiated SIADH from most other causes of hyponatremia. Beck 
observed that in 16 out of 17 patients with SIADH the serum urate levels were in the hypouricemic 
range. Hypouricemia is due to high uric acid clearance rates that results from the decrease in tubular uric 
acid reabsorption at the proximal tubule which occurs in SIADH due to increased extracellular volumes 
which in turn increases the fractional excretion of urea. 33,34 Expansion of extracellular fluid volume 
increases and contraction of extracellular fluid volume decreases the clearance of urate. In SIADH, there 
is volume expansion associated with low uric acid. A comparable situation is observed whenever 
exaggerated amounts of free water are consumed. Serum uric acid values more than 5mg/100ml are seen 
in patients with hyponatremia associated with a decrease in extracellular volume. 33 High uric acid values 
are also seen in the elderly who have lower glomerular filtration rates. Values less than 4mg/100 ml have 
also been observed in hypocortisolism, diuretics, potomania, cirrhosis and renal salt wasting. 33 CSW has 
been associated with normal, high or sometimes unexpectedly low levels of uric acid that persist despite 
correction of the hyponatremia. 2,11,21,25,35,36 
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 MATERIALS AND METHODS 
 
We conducted a prospective study in our institution between August 2011 and February 2014 on post-
operative neurosurgical patients who developed hyponatremia and natriuresis.  Hyponatremia in this 
study was defined as a serum sodium less than 130 mmol/L and natriuresis as a urine spot sodium more 
than 25meq/l.2,37  
Volume status was described, on the basis of CVP, as hypovolemic (< 5 cm of water), normovolemic (6-
10 cm of water), and hypervolemic (> 13 cm of water).1 The CVP was measured through a catheter that 
was passed through the antecubital, femoral or subclavian veins. Anemia was defined by a hematocrit of 
less than or equal to 27%. Normal hematocrit was equal to 28 to 48%.2 
We included all non trauma postoperative neurosurgical patients who developed hyponatremia and 
excluded postoperative neurosurgical patients who were on diuretics, osmotically active agents (e.g. 
Mannitol) or had hypocortisolism or congestive cardiac failure. 
 
76 patients of the 2950 postoperative patients who underwent neurosurgery in one Neurosurgical unit of 
the department developed hyponatremia. Of these 31 met the inclusion criteria and were recruited into 
the study while 45 patients with hyponatremia were excluded. Urine spot sodium was sent for all patients 
with hyponatremia to check for natriuresis.  Packed cell volume (PCV), serum cortisol, plasma and urine 
osmolality was sent for all patients with hyponatremia and natriuresis. Patients with anemia would 
undergo blood transfusion or receive medications to correct their hyponatremia. Patients without anemia 
had a central line inserted and blood samples were sent for antidiuretic hormone (ADH), aldosterone, NT 
pro-BNP and uric acid. Serial serum sodium measurements were recorded. The total intake of fluids and 
output were measured. The study was divided into 2 phases.   
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 Phase 1 
 
In the first phase of the study we explored the feasibility of using serum markers to differentiate SIADH 
from CSW as a cause for hyponatremia with natriuresis.  For this, we used central venous pressure, as 
this had been previously validated by our department in earlier studies. Once the differentiation was done 
based on the CVP, hypovolemic patients were treated with fluid resuscitation and oral salt 
supplementation while patients who were either euvolemic or hypervolemic underwent fluid restriction 
with oral salt supplementation. Hypertonic saline was reserved for patients who were symptomatic for 
hyponatremia such as those who presented with seizures or altered sensorium.   These patients were 
monitored on a regular basis with serial measurements of serum sodium and a strict intake output chart. 
This was continued till patients attained a serum sodium of 130 mEq/L.  
 
While inserting the central line we also took blood samples for antidiuretic hormone (ADH), aldosterone, 
NT pro-BNP and uric acid. The final diagnosis of SIADH or CSW was made based on the volume of 
fluid taken by the patient everyday during the duration of his illness. An intake of less than 2 liters over a 
period of 24 hours was considered as fluid restriction. The values of antidiuretic hormone (ADH), 
aldosterone, NT pro-BNP and uric acid were now compared with the final diagnosis. The normal value 
of NT pro-BNP in adults is less than or equal to 125 pg/ml. Hence, we chose this value as a cut off to 
differentiate between SIADH and CSW. 
 
 
 
 
 
 
  39
 Phase 2 
In Phase-2 we used this cut-off value of NT proBNP to treat 21 patients as SIADH or CSW until the 
serum Na+ normalized.  Patients with SIADH were managed with fluid restriction and sodium 
replacement. Patients with CSW were managed with appropriate IV fluids + oral salt. The sodium deficit 
was calculated using the following formula: 0.6 (weight in Kg) x (desired sodium – actual sodium);   0.5 
for women 
Hyponatremia was corrected at the rate of 10 – 12 mEq/l in the first 24 hours and < 18 mEq/l in the first 
48 hours.  Hypertonic saline was given in cases of patients symptomatic for hyponatremia or those with a 
sodium less than 120 mEq/L.  The primary outcome of the study was correction of hyponatremia (serum 
sodium values of > 130 mEq/L 
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 RESULTS AND ANALYSIS 
 
A total of 31 patients were recruited into the study. They included 18(58%) males and 13(42%) females. 
The ages varied from 28-71 years with a median age of 46 years. 
  
Table 4: The underlying diagnosis in these patients is as follows: 
Pituitary adenoma     11 
Glioma      5 
Suprasellar cysts     3 
Vestibular Schwannoma    2 
Tuberculous meningitis with hydrocephalus  2  
Colloid cyst      1 
Tuberculum sella meningioma   1 
Planum sphenoidale meningioma   1 
Craniopharyngioma     1 
Aneurysm      1 
Lymphoma      1 
Intramedullary tumor     1 
Cervicomedullary Hemangioblastoma  1 
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Hyponatremia was corrected in all the patients.   
In Phase 2 where the management was based on NT pro-BNP, the mean time duration to correct 
hyponatremia was 2.8 ± 1.63 days with a range of 1-8 days. 
Figure 7:  Time taken for correction of hyponatremia in patients in Phase 2 
 
NT pro-BNP 
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Phase 1 
Table 5: Patients in Phase 1 with their diagnosis, age, sex, CVP, NT pro-BNP, Aldosterone, Uric acid, 
type of fluid management and outcome 
S.no Diagnosis Sex Age CVP NTproBNP Ald Uric acid 
Fluid 
restricted
Sodium 
corrected
1 Atypical pit. adenoma M 30 8 54.8 84 2.7 Y Y 
2 TBM with hydrocephalus F 35 3 222.7 50 1 N Y 
3 R frontal lymphoma F 60 7 96.1 80 2.2 Y Y 
4 3rd ventricular colloid cyst M 40 7 42.49 56 3.1 N Y 
5 
Atypical choroid PLX 
papilloma F 35 0 1053 874 4.3 N Y 
6 GH secreting pit adenoma F 30 9 49.98 15 1.8 Y Y 
7 
Tuberculum sellae 
meningioma F 44 12 403.5 9.2 3.1 N Y 
8 TBM with hydrocephalus F 48 0 1210 25 1.9 N Y 
9 
Post-op L vestibular 
schwannoma M 66 7 348.8 18 2 Y Y 
10 Suprasellar epithelial cyst F 49 4 292.8 21.8 2.1 N Y 
 
2 patients (serial nos. 4, 7) with high CVP did not comply with fluid restriction. Their sodium however 
improved with their fluid intake and hence were considered as having CSW. One patient (serial no. 7) 
had a high CVP and NT pro BNP and improved with fluid restriction.  
 
The first 10 patients were categorized into SIADH and CSW on the basis of their initial CVP. Of the 4 
patients with a CVP less than 5 cm all had a concordant NT pro-BNP more than 125 pg/ml. However, of 
the 6 patients with a CVP more than 5 cm, 4 had an NT pro-BNP less than or equal to 125 pg/ml while 
the other 2 had a discordant NT pro-BNP more than 125 pg/ml. This is depicted in the table below: 
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Table 6:  Correlation of NT proBNP values with CVP 
         NT proBNP      CSW   (CVP < 5 cm)       SIADH (CVP > 5 cm) 
    NTproBNP( > 125pg/ml)                    4                       2 
   NTproBNP( ≤ 125 pg/ml)                    0                       4 
 
The above table gives NT proBNP a sensitivity of 100% and a specificity of 66.7% in detecting 
hypovolemia based on central venous pressure. The p value based on Fisher exact test was 0.07. The 
positive predictive value for predicting hypovolemia is 66.7% and the negative predictive value is 100%. 
 
Table 7:  In this table we have looked at the patients from the point of view of whether their serum 
sodium improved with fluid resuscitation or fluid restriction. The NT proBNP values in these patients 
have been correlated to their fluid intake. Based on this we get the following table 
Of the 6 patients whose hyponatremia responded to fluid resuscitation 5 patients had an NT pro-BNP 
more than 125 pg/ml as expected while one patient had an NT pro-BNP less than 125 pg/ml. Similarly, 
of the 4 patients whose hyponatremia responded to fluid restriction 3 patients had an NT pro-BNP less 
than 125 pg/ml as expected while one patient had an NT pro-BNP more than 125 pg/ml. This can be seen 
in the following table 
            NT proBNP    Pts who responded to fluid   
             resuscitation 
   Pts who responded to fluid 
                 restriction 
   NTproBNP(> 125pg/ml)                       5                        1 
   NTproBNP(≤ 125 pg/ml)                       1                        3 
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The above table gives NT proBNP a sensitivity of 83.3% and specificity of 75% to detect CSW based on 
the cut off value of 125 pg/ml. The positive predictive value of NT proBNP for predicting CSW is 83.3% 
and the negative predictive value is 75%. The p value based on Fisher exact test was 0.191. 
 
Phase 2   
Based on these results we proceeded to manage the remaining patients on the basis of their NT proBNP 
values alone. Patients with NT proBNP ≤ 125 pg/ml were treated as SIADH and those with NT proBNP 
> 125 pg/ml were treated as CSW.  The results obtained were as follows. 
9 of the 10 patients who required fluid resuscitation had an NT pro-BNP more than 125 pg/ml while all 
11 patients whose hyponatremia corrected with fluid restriction has an NT pro-BNP less than 125 pg/ml. 
 
Table 8:  Correlation of management based on NT proBNP values with the final diagnosis of either 
SIADH or CSW in Phase 2 
NT proBNP      CSW (Correction of  
hyponatremia with fluid resuscitation)
    SIADH (Correction of  
hyponatremia with fluid restriction)
NTproBNP (> 125pg/ml)                         9                       0 
NTproBNP (≤ 125 pg/ml)                          1                       11 
 
This gave us a sensitivity of 90 % and a specificity of 100% for NT proBNP to detect CSW. The positive 
predictive value to predict CSW was 100% and the negative predictive value was 91.67%. The p value 
based on Fisher exact test was < 0.001. 
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Table 9:  Combining the results of the 31 patients based on their fluid intake we get the following 
cumulative result (phase 1+2) 
NT proBNP                 CSW                    SIADH 
NTproBNP (> 125pg/ml)                   14                          1 
NTproBNP (≤ 125 pg/ml)                     2                         14 
 
 
NT proBNP had an overall sensitivity 87.50% of and a specificity of 93.33% to detect CSW. The 
positive predictive value to detect CSW was 93.33% and the negative predictive value is 87.50 %. The p 
value based on Fisher exact test was < 0.001. 
 
Serum Aldosterone 
All our patients had their blood samples taken in the recumbent position. 
Patients with SIADH in our study had a serum aldosterone which ranged between 3.8 to 229 pg/ml with 
a mean of 54.33± 58.47 pg/ml. 
Patients with CSW had an aldosterone between 9.2 to 874 pg/ml with a mean of 98.75 ± 225.28 pg/ml. 
 
Uric Acid 
The normal range of uric acid varies between 3-6 mg/dl in females and between 4-7 mg/dl in males. 
Female patients with SIADH had their uric acid range between 1.4-3.8 mg/dl with a mean of 2.1 ± 0.86 
mg/dl. Male patients with SIADH had their uric acid range between 1.2-6.3 mg/dl with a mean of 3.3 ± 
1.59 mg/dl  
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Female patients with CSW had their uric acid range between 1-4.3 mg/dl with a mean of 2.3 ± 1.1 mg/dl 
Male patients with CSW had their uric acid range between 2-6.3 mg/dl with a mean of 3.44 ± 1.3 mg/dl. 
 
ADH 
The normal serum range for ADH is up to 13 pmol/l. The ADH assay kit did not perform well and the 
ADH assay had to be abandoned during the study.  
 
Urine Spot Sodium 
In patients with SIADH the urine spot sodium ranged between 54-229 mmol/l with a mean of 118 ± 
46.94 mmol/l 
In patients with CSW the urine spot sodium ranged between 42-233 mmol/l with a mean of 129.18 ± 60 
mmol/l. 
 
We found that the values of serum aldosterone, uric acid and ADH coincided in patients with SIADH 
and CSW and hence these markers did not give us a tool that could be used to differentiate between 
SIADH and CSW.  
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DISCUSSION 
 
Neurosurgery patients develop hyponatremia in the setting of natriuresis.2 Hyponatremia with natriuresis 
is caused by either the syndrome of inappropriate anti diuretic hormone (SIADH) or cerebral salt wasting 
(CSW). 2 Opinion on how common SIADH and CSW are varies. Some authors argue that the existence 
of CSW is overstated. 38 These authors noted a connection between the rise in use of triple H therapy and 
CSW stating that large infusions of saline were causing pressure natriuresis and hence a negative balance 
of sodium along with a contracted extracellular fluid status which was being reported as CSW. Whereas 
others report that it is at least as common, if not more, than SIADH.18,22  A recent study by Sherlock et al 
6 on 116 patients with hyponatremia showed SIADH in 62%, CSW in 4.8% and diuretic induced 
hypovolemic hyponatremia in 26.7%.  In our study, of the 31 patients having hyponatremia with 
natriuresis, we found SIADH in 15 (48.38%) and CSW in 16 (51.61%). The overall prevalence of 
postoperative hyponatremia with natriuresis in postoperative patients undergoing neurosurgery in our 
study was 1.05%. 
 
The differentiation between SIADH and CSW has been difficult due to overlapping clinical and 
biochemical features and hence, it is based on the extracellular fluid status of the patients with SIADH 
being euvolemic or slightly hypervolemic and CSW being hypovolemic. 11  There remains a significant 
delay in the diagnosis and management of hyponatremia which increases the morbidity and mortality of 
these patients.  
 
The determination of fluid status has been done using physical signs such as hypotension and 
tachycardia, laboratory markers like hematocrit, or blood urea nitrogen concentrations or by invasive 
methods using either radioisotope based volume studies 22 or using a central line. 1 Chung et al 39 showed 
that clinical assessment correctly identified only 47 percent of hypovolemic patients and 48 percent of 
normovolemic patients out of the 58 patients included in the study. 
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Radioisotope studies are not routinely used and are often difficult to undertake. In a previous study done 
in our department, Damaraju et al 1 used CVP measurement to determine the course of treatment for 
patients with hyponatremia. In their study based on CVP, 19 of 25 patients attained normal serum 
sodium values within 72 hours, and an additional 3 responded within the next 36 hours (108 h after entry 
into the study). One patient who was discharged on request had normalized her serum sodium a week 
later. In our study based on NT proBNP 23 of the 31 patients normalized their serum sodium values 
within 72 hours, and an additional 5 responded within the next 24 hours. 
 
However newer meta-analyses have cast doubts whether central venous lines accurately measure blood 
volume and fluid responsiveness. Marik et al40 did a meta-analysis of 24 studies which included 803 
patients. Pooled correlation coefficients vary from -1 to +1 where -1 is a negative correlation, 0 means 
there is no correlation between the variables and +1 means a perfect correlation between the variables. 
The pooled correlation coefficient between CVP and measured blood volume was 0.16 (95% confidence 
interval [CI], 0.03 to 0.28). 40 Overall, 56 ± 16% of the patients included in this review responded to a 
fluid challenge. 40  The pooled correlation coefficient between baseline CVP and change in stroke 
index/cardiac index was 0.18 (95% CI, 0.08 to 0.28). 40  The pooled correlation between change in CVP 
and change in stroke index/cardiac index was 0.11 (95% CI, 0.015 to 0.21). 40 The review thus 
demonstrated a very poor relationship between CVP and blood volume as well as the inability of 
CVP/change in CVP to predict the hemodynamic response to a fluid challenge. 40 They concluded that 
CVP should not be used to make clinical decisions regarding fluid management.  
 
The laboratory markers mentioned previously are not routinely done in clinical practice. Thus, there is 
no way to accurately differentiate SIADH and CSW. 41 Hence there is a need to explore other serum 
markers towards this end. While a number of serum markers have been identified, there are very few 
studies which have used them to differentiate SIADH and CSW. We therefore chose to look at NT pro 
BNP, uric acid, aldosterone and ADH in an attempt to evolve a less invasive and reliable way to 
differentiate between SIADH and CSW. 
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NT pro-BNP 
Several previous studies have shown a rise in serum BNP concentration after subarachnoid hemorrhage 
19 which is a common cause of CSW. 25  All 10 patients of Berendes with subarachnoid hemorrhage and 
CSW had elevated levels of BNP. 28 He also found that the levels of BNP and urinary sodium had a 
linear correlation. 
 
 McGirt et al found that 10 (63%) of 16 patients who experienced a large (more than threefold) increase 
in BNP in their cohort of 40 patients with SAH developed hyponatremia. 6 (25%) of 24 patients 
experiencing a minimal (less than threefold) increase in admission serum BNP level also developed 
hyponatremia 20. 
 
We chose to look at NT proBNP as a marker to differentiate SIADH from CSW based on the literature 
on increased levels of natriuretic peptides in patients with CSW. To our knowledge this is the first study 
to look at NT proBNP in hyponatremia and also the first attempt at using this molecule to differentiate 
SIADH from CSW. Previous studies had mainly looked at BNP in subarachnoid hemorrhage.  
 
In the first part of our study we had used a central line to categorize our patients into hypovolemic, 
euvolemic and hypervolemic categories based on the study by Damaraju et. al1. In the study by 
Damaraju et al1 there were 19 patients with hypovolemia who were treated with fluid resuscitation and 
salt intake and only 7 patients who were normovolemic. The normovolemic patients were treated with 
normal fluid intake (volume not defined in the study) and additional salt. There were no patients who 
were hypervolemic. Based on current literature12 we believe that the normovolemic patients have SIADH 
and require fluid restriction for effective correction of sodium. As the fluid balance of the patients who 
were normovolemic in Damaraju's study is not known, it could be possible that these patients had a low 
intake of fluids that would be normal for them under their circumstance. If these normovolemic patients 
consume large quantities of water, their hyponatremia would be exacerbated. 
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Hence, we used a CVP cut off of 5 cm of water to differentiate between SIADH and CSW. NT proBNP 
based on a cut off of 125 pg/ml did not correlate in 2 patients with a CVP more than 5 cm. While one 
patient improved with fluid restriction confirming the CVP diagnosis of SIADH, the other patient 
improved with fluid resuscitation confirming the diagnosis of CSW based on NT proBNP.  
 
We found that NT pro BNP values were ≤ 125 mEq/L (i.e. within the normal range) in patients with 
SIADH and > 125meq/L in patients with CSW. This was in line with what we had predicted for NT 
proBNP based on previous studies. We therefore, decided to use 125 mEq/L as the cut off for NT 
proBNP to differentiate between SIADH and CSW. We found that NT proBNP based on this cut off had 
a good correlation with both the results of CVP, and the diagnosis of SIADH/CSW on the basis of fluid 
management. 
 
Overall, NT proBNP values did not correlate with the fluid management used in 3 patients. 2 patients 
with SIADH based on NT proBNP improved with fluid resuscitation showing them to be cases of CSW 
rather than SIADH while one patient with CSW based on NT proBNP improved with fluid restriction 
instead. Thus we had 2 patients with false negative values and one patient with a false positive value of 
NT proBNP. This gave NT proBNP based on a cut off of 125pg/ml a sensitivity 87.50% of and a 
specificity of 93.33% in differentiating between SIADH and CSW. This finding correlates well with the 
findings of previous authors who detected high levels of BNP in SAH. It is well known that SAH is a 
common cause for CSW.19 Our study showed high values of NT proBNP in patients with CSW.  NT 
proBNP was also found to correlate well hypovolemia indicating that it could be used as a less invasive 
marker of the hydration status in patients with hyponatremia. The mechanism by which BNP causes 
CSW is through increase in glomerular filtration rate, inhibition of sodium reabsorption, opposition of 
the action of vasopressin and inhibition of mineralocorticoid synthesis. 19  
The mechanisms by which a CNS abuse of any sort leads to increased levels of natriuretic peptides are 
still being theorized. Some of them include: 
(1) Direct damage to cortical and sub cortical structures where BNP exists leads to its unintended release 
into the circulation.  
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(2) Production and release of natriuretic peptides from the hypothalamus in disease states, such as SAH, 
to serve a protective role against elevated intracranial pressure.  
(3) Myocardial tissue has also been proposed to be a source of elevated natriuretic peptide levels in 
CSW. Surges in sympathetic outflow in acute CNS injury leads to catecholamine- induced myocardial 
ventricular strain, thereby causing release of BNP from the atrial myocardium.  
(4) Hypervolemic therapy itself, which is frequently administered after SAH can lead to myocardial 
chamber stretch and release of these peptides. 19 
NT proBNP is thus a good marker to distinguish CSW from SIADH. This marker is easily obtained from 
a blood sample thus avoiding the need for any invasive monitoring. NT proBNP has been used by the 
cardiologists as a prognostic marker in cardiac failure and hence the test kits for NT proBNP are widely 
available and not costly. The results are generally available within one hour and hence can be used for a 
quick diagnosis of hyponatremia with natriuresis.  
 
Our results with NT proBNP need to be tested over a larger population and thus this study was limited 
by its small sample size. Also this marker cannot be used in patients with cardiac failure as the NT 
proBNP levels in these patients would be high. 
 
Serum Aldosterone 
Fichman et al42 studied 4 patients with SIADH and found normal levels of aldosterone.  All 10 patients 
studied by Berendes28 with subarachnoid hemorrhage and CSW had low levels of aldosterone. Low 
levels of aldosterone in CSW have also been shown by other authors. 43 
 
However, contrary to the available literature we found that serum aldosterone levels were inappropriately 
low in both SIADH and CSW. Patients with SIADH had a serum aldosterone with an average of 48.35 ± 
55.82 pg/ml while those with CSW had an aldosterone with mean of 109.45 ± 242.9 pg/ml. While Brain 
natriuretic peptide is known to suppress aldosterone in CSW, the mechanism due to which low levels of 
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aldosterone could be found in SIADH needs to be worked out. Thus aldosterone was not useful in 
differentiating between SIADH and CSW. Our study showed that hyponatremia with natriuresis is 
associated with levels of aldosterone in the lower side of the normal range irrespective of the cause being 
SIADH or CSW indicating a possible role for addition of mineralocorticoids like Fludrocortisone in the 
management of both SIADH and CSW. 
 
Uric Acid 
Beck 32 proposed that the coexistence of hyponatremia and hypouricemia (defined as serum urate less 
than or equal to 4 mg per 100 ml) differentiated SIADH from most other causes of hyponatremia. Beck 
observed that in 16 out of 17 patients with SIADH the serum urate levels were in the hypouricemic 
range. 
 
In our study we found that the serum uric acid levels overlapping in both patients with SIADH and 
CSW.   Our study also showed that hyponatremia with natriuresis is associated with hypouricemia 
irrespective of the cause being either SIADH or CSW. Thus this assay is not a reliable marker of either 
volume status or in distinguishing between SIADH and CSW. This finding has been confirmed by 
investigators like Maesaka36 who therefore tried to look at the rate of correction of hypouricemia and 
fractional excretion rates of urate following correction of SIADH and CSW rather than at hypouricemia 
itself.  
 
Antidiuretic hormone (ADH) 
Serum ADH levels are known to be inappropriately elevated in up to 90% of patients with SIADH.33,44 
However SIADH has also been documented in patients with no detectable ADH. 2 We wanted to 
evaluate this point in our study but this had to be abandoned because of the poor performance of the kit 
used for ADH assay. 
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With the development of sensitive vasopressin radioimmunoassays capable of detecting the small 
physiologic concentrations of ADH that circulate in plasma there was hope that measurement of plasma 
vasopressin levels might become the definitive test for diagnosing SIADH. This has not occurred for 
several reasons. First, although plasma vasopressin levels are elevated in most patients with this 
syndrome, the elevations generally remain within the normal physiologic range and are abnormal only in 
relation to plasma osmolality. Second, 10% to 20% of patients with SIADH do not have measurably 
elevated plasma vasopressin levels and are at the limits of detection by radioimmunoassay. Third, and 
perhaps most important, most disorders causing solute and volume depletion or decreased EABV are 
associated with elevations of plasma vasopressin secondary to nonosmotic hemodynamic stimuli. 45 
 
The main limitation of our study was the small sample size. This was due to the fact that hyponatremia 
with natriuresis due to SIADH or CSW in patients undergoing neurosurgery is not very common. A 
larger sample size would have enabled us to obtain a cut off value of NT pro-BNP with the highest 
predictive value. 
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 CONCLUSION 
 
1. NT Pro-BNP is a useful marker to differentiate SIADH from CSW. A cut off value of 125 pg/ml could 
differentiate SIADH from CSW with a sensitivity 88.23% of and a specificity of 92.85% with a positive 
predictive value to detect CSW of 93.33%. 
We would like to recommend NT pro-BNP as a readily available, quick and reliable marker to 
differentiate between CSW and SIADH. 
2. Serum Aldosterone values were found to be inappropriately low in patients with both CSW and 
SIADH. Fludrocortisone would be beneficial for treating patients with both these conditions. 
3. Serum Uric acid levels do not help differentiating SIADH from CSW. 
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APPENDIX I   Table 1: The various assays, their methods of estimation, reference ranges and 
instruments used are given in the table below 
 
ASSAY 
TECHNIQUE MEASURING 
 RANGE 
REF RANGE INSTRUMENT 
ALDOSTERONE
Radioimmunoassay, SIEMENS,  
USA,   
COAT-A-COUNT 
16.0 -  1200.0 
 pg/ml 
SERUM: 10-160 
lying;  
40-310 pg/ml 
 standing 
WALLAC 1470 
GAMMA COUNTER, 
FINLAND 
ADH Radioimmunoassay, 
DIAsource, Belgium 
0.5-60 
 pmol/L 
PLASMA:  
up to 13 pmol/L 
WALLAC 1470  
GAMMA COUNTER, 
FINLAND 
CORTISOL        
           
Automated 
Chemiluminiscent immunoassay,    
 
0.2 – 50.0  
g/dL 
SERUM:  
7-25 g/dL 
 (0800am) 
SIEMENS 
BAYER CENTAUR 
 XP, USA 
NT-pro-BNP 
Automated 
 Chemiluminiscent Immunoassay 
20-35,000  
pg/ml 
Up to 125 pg/ml  
(<75yrs); up to  
450 pg/ml (>75yrs) 
SIEMENS  
IMMULITE  
2000XPi, USA 
OSMOLALITY  
Freezing point depression  
   Osmometer 
100 – 2500  
mOsmol/kg 
SERUM 2
mOsm/Kg. URINE
1400 mOsm/Kg 
GONOTEC  
OSMOMETER,  
GERMANY 
SODIUM  
Ion selective electrode 
Automated Chemistry Analyzer 
50 – 200  
mmol/L 
SERUM 135-145 m
URINE: M 40-220,
287 mmol/L 
Roche, Modular P800, 
GERMANY 
URIC ACID  
colorimetric, enzymatic, end-
uricase, peroxidase.   
Automated Chemistry Analyzer 
 
0.5 – 20.0  
mg/dL 
SERUM: M 
mg/dL, F 3.0-6.0 mg
Roche, Modular P800, 
GERMANY 
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SNO Hospital Number Sex Diagnosis CVP Symptomatic NT- proBNP Aldosterone Uric acid ADH Urine spot Na
1 001082F M Atypical pit. adenoma 8 N 54.8 84 2.7 159
2 997082D F TBM with hydrocephalus 3 Y 222.7 50 1 1.41 59
3 030479F F R frontal lymphoma 7 Y 96.1 80 2.2 < 0.5 98
4 009286F M 3rd ventricular colloid cyst 7 N 42.49 56 3.1 0.55 35
5 607731B F Atypical choroid PLX papilloma 0 N 1053 874 4.3 4.5 205
6 099870F F GH secreting pit adenoma 9 N 49.98 15 1.8 < 0.5 166
7 814192D F Tuberculum sellae meningioma 12 N 403.5 9.2 3.1 < 0.5 116
8 092066F F TBM with hydrocephalus 0 Y 1210 25 1.9 7.32 116
9 993615D M Post-op L vestibular schwannoma 7 Y 348.8 18 2 < 0.5 229
10 138073F F Suprasellar epithelial cyst 4 Y 292.8 21.8 2.1 < 0.5 150
11 172765F M Gonadotroph Pit. Adenoma 12 N 71.79 26 4.4 < 0.5 93
12 175641F F Non Funct Pit Adenoma 12 N 96.58 3.8 3.8 < 0.5 73
13 115762F M Suprasellar Arach cyst, Meningitis 12 Y 104 4.6 3.9 < 0.5 155
14 874610D M GH secreting pit adenoma 10 Y 15.89 54.6 1.2 < 0.5 117
15 115489F M Post op L VS 4 Y 605 Hemolysed 2.5 < 0.5 79
16 155895F M Non Funct Pit Adenoma 10 Y 459.2 10 2 < 0.5 161
17 193625F M Non Funct Pit Adenoma 9 Y 76.52 88.3 3.5 < 0.5 54
18 067396F M Non Funct Pit Adenoma 8 N 121 < 10 2.3 < 0.5 62
19 271752F F R Insular Oligodendroglioma 12 Y 121.6 < 10 1.4 < 0.5 137
20 254226F F Planum Sphenoidale meningioma 2 Y 468.5 < 10 2.4 0.51 175
21 322286F F Oligodenroglioma 8 Y 191 26.5 1.4 < 0.5 119
22 260633F M Craniopharyngioma, Meningitis 5 N 207.7 117 3.5 5.43 233
23 331338F M R A1-A2 aneurysm 0 Y 183.3 49 3.7 < 0.5 110
24 319421F F Sellar arachnoid cyst 10 Y 26.1 83.4 1.6 < 0.5 137
25 385963F M Right temporal GBM 10 Y 334 54 6.3 96
26 670117C M Right frontal GBM 12 Y 7.75 81 2.6 144
27 861592B M Right frontal fungal mass N 124.8 229 4.8 79
28 772672F M Pit adenoma Y 133.7 75.5 2.1 216
29 473465F M Cervicomedullary hemangioblastoma N 375.4 Not ready 3.9 42
30 724818f M GH secreting pit adenoma Y 58.14 18.29 6.3 136
31 453160D F Pituitary adenoma N 97 13.6 2 86
Master Table 
D1 D2 D3 D4 D5 D6 D7 D8
Post-op Na
Master Table C
1 001082F 117/117 118/123 131/134 134/135
950/80
0
3500/2
1385/1
500
3850/2
890/1
150
4515/
1050/2
780
2190/1
1150/3
310
2270/4
850/22
40 SIADH SIADH SIADH
CSW
2
3
4
997082D
030479F 
009286F
126
126
127
133/135
128/127
129
000
2280/ 
VB
2925/2
300
2250/4
800
1850/V
B
2400/3
200
1350/1
2550
975/V
B
2175/
2260
990
1725/1
880
500 CSW
SIADH
3150/8
50 SIADH
CSW
SIADH
SIADH
CSW
128
130
130
131
SIADH
CSW
CSW5
6
607731B 
099870F 
128
128
137 139
123/120 122/121 128/136 140
100 090 CSW
2100/1
700
1750/2
750
1500/
1850
1150/1
750 SIADH
SIADH SIADH
7
8
814192D 
092066F 
124
116
126/123
120/123
125/129
129
136/130 136
133
2490/1
600
2440/1
950
2400/2
2775/1
450
3200/3
600
2855/1
6330/
4680
2835/
2620
2020/
2635/2
650
3350/2
350 SIADH
CSW
1785/1 2375/1 1800/1 1670/2
CSW
CSW
CSW
CSW
CSW
SIADH
9
10
993615D
138073F
128
123
126
132
125
135/129
123 124 130 132
131/137
275
4700/1
500
500
4400/8
50
1600
4575/
900
450 250 920 275 SIADH
4775/4
500
3075/2
700 CSW CSW CSW
11 172765F 127/127 127/133 134 136
2280/3
830
2050/1
450
1600/
2270
SIADH SIADH
D1
ontd.
D2 D3
Final 
diag 
CVPD4 D5 D6 D7SNO
Final diag 
NT 
proBNP
Final diag 
fluid mngtHNUM
12 175641F 126/129 139
2425/2
600
1900/1
800
1950/
1750
2000/2
500
2150/2
300
SIADH SIADH
13 115762F 129 126/129 136
3725/2
300
2050/1
875
2375/
1300
2425/2
150
2700/2
225
3175/2
500
SIADH CSW
14 874610D 118/119 122/127 136
2680/2
880
1650/2
050 SIADH SIADH
15 115489F 126 128/130 136
3125/6
00vb
2935/6
75vb
CSW CSW
16 155895F 112/111 115/121 128/128 131/135
1610/1
525
3850/2
000
4100/
1900
4070/2
900
CSW CSW
17 193625F 116/113 116/125 124/130 132/133 135
2275/3
700
1325/4
000
680/8
00
1400/1
560 SIADH SIADH
18 067396F 121 132/131 135
2150/1
500
2050/2
100
2300/
2570
SIADH SIADH
19 271752F 128/126 128/128 131/129 131/132
1400/1
220
830/83
0
1295/
770
825/11
70
890/15
10
880/15
30 SIADH SIADH
20 254226F 129/136 139
4425/1
900 CSW CSW
21 322286F 122/123 126/124 131/130
1320/3
150
2150/3
100
1505/
1200
1050/V
D
CSW CSW
22 260633F 125 122/136
2650/1
750
4150/1
800
2875/
1350
3350/1
600
CSW CSW
23 331338F 122/121 126/127 126 130
3600/2
600
5570/4
550
4900/
4500
4500/4
400
CSW CSW
24 319421F 124 121/125 133 128/133 132
1190/1
550
845/30
0
1000/
570
1000/1
270
1000/1
360 SIADH SIADH
25 385963F 120 117/119 125/124 127/131 136/137
2754/6
50
3470/2
120
2945/
1900
2210//
2250
CSW CSW
26 670117C 128 134/127 135 700/VB
1200/1
950
800/5
50 SIADH SIADH
27 861592B 126/121 117/125 127/126 129 122 129/129
132/1
29 140
1850/1
930
920/24
50
1450/
650
1300/9
00
1150/9
50
1200/1
300
1100/1
000 SIADH SIADH
28 772672F 117 114/114 111/120 122/129 132/132
1975/1
200
2550/2
450
2400/
2300
1950/1
800
1900/1
850
CSW CSW
29 473465F 127 138
2350/1
700 CSW CSW
30 724818f 114/114 118/125 125/130 130/135
1150/2
400
960/15
00
2990/
6950
700/90
0
SIADH SIADH
31 453160D 127 127/127 131/135 138
3600/3
900
875/34
50
1100/
690
1100/1
300 SIADH SIADH
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PROFORMA FOR EVALUATION OF POSTOPERATIVE HYPONATREMIA AND NATRIURESIS 
 
S.No: 
Date: 
Name: 
Age: 
Hospital No.: 
Diagnosis: 1) 
       2) 
       3) 
Date of Surgery:        Previous Surgery: 
Type of Surgery:       Previous RT: 
 
 
PREOPERATIVE HORMONAL PROFILE FOR PITUITARY PATIENTS 
T4        8AM Cortisol 
FTC        FSH 
TSH        LH 
Prolactin       Testosterone 
HGH        IGF-1 
 
Post-operative  Sodium 
Day   1  2 3 4 5 6 7 8 9 10 11 12 13 14 15 
 
Post-operative Cortisol   day 1  day2  day3 
 
 
Day of onset of hyponatremia:  Day …. (after surgery) 
CVP: 
Symptomatic: Y /N 
INVESTIGATIONS SENT: 
Uric acid        Cortisol 
BNP         Aldosterone 
ADH         TFT 
Urine spot Sodium       
Time to normalize: 
 
 
 
 
  
Treatment:  
 Medication   Dose    Day1 Day2 Day3 
 Hydrocortisone 
Fludrocortisone 
3% Saline   Y / N 
ICU required    Y / N 
Fluid restriction Y / N 
Intake / Output 
Day  1  2  3  4  5  6  7   
 
 
  
